Dr. Sherene Min brings to ViiV Healthcare extensive drug development and infectious disease experience along with strong team management skills. As a physician scientist with knowledge and experience in translational medicine and late-state drug development, she has a proven record in drug development including successful regulatory interactions with US and international agencies. She holds therapeutic expertise in HIV, hepatology, and rare diseases, and has additional expertise in clinical pharmacology and drug safety. Her excellent presentation skills have afforded her many opportunities to speak at scientific conferences, investigator meetings, and in regulatory interactions and internal oversight boards.
As Head Unit Physician for ViiV, Sherene has international responsibility for ViiV physicians who are in medical governance roles in support of clinical development. She ensures physician readiness for research and development roles, provides medical governance and compliance training, develops physician capabilities and talent, and builds a ViiV physician community that fosters shared learnings and best practices. In another capacity, Sherene serves as ViiV’s Medicine Development Leader for the Maturation Inhibitor Portfolio, with accountability for the delivery of development programs, prioritizing the portfolio, and providing clinical input to and management of involved ViiV physicians.
Prior to ViiV, Sherene held an industry position with Roivant Sciences as Vice President of Clinical Research, where she managed the Rare Diseases portfolio including academic collaborations, medical governance for rare disease and hepatology projects, and clinical and medical input for due diligence activities. Previously, she was with GSK for twelve years, advancing to Medicine Development Leader in increasingly complex roles in discovery medicine and clinical development. Her work focused primarily on HIV entities, including the integrase inhibitor program as the clinical leader for the dolutegravir program and early clinical development leader for cabotegravir. She had an additional focus on safety as a member of the GSK QT advisory committee and the Cardiac Safety Research Consortium, a public- private research partnership including the FDA, other industry partners and Duke University. In addition, as Adjunct Clinical Assistant Professor, Sherene provided oversight of clinical fellows and physician extenders at the University of North Carolina (UNC) Infectious Diseases outpatient clinic until 2009.
Sherene completed her undergraduate work at UNC at Chapel Hill, and earned her MD from UNC School of Medicine in 1997. She completed an internal medicine residency at Washington University School of Medicine in St Louis, and an infectious diseases fellowship at UNC School of Medicine while concurrently earning a MPH from UNC School of Public Health.
Sherene considers herself lucky to have landed in Chapel Hill, NC, a “lovely and diverse college town” she fell in love with while attending UNC. She lives there now with her husband and their two boys, who bring tremendous joy to their parents. Sherene finds time to run, cook, and dance, especially to East coast swing and Latin rhythms. Active in their church, she and her family also volunteer at an underserved school and an extended stay house for UNC hospital patients and families.